Skip to main content

Table 1 Baseline characteristics of the study population

From: Variation in the human soluble epoxide hydrolase gene and risk of restenosis after percutaneous coronary intervention

Characteristic

CHD cases

(n = 435)

Controls

(n = 274)

Age at recruitment

61 ± 8.9

59 ± 9.6

Men

365 (83.9)

129 (47.1)

BMI -- kg/m2

28 ± 3.5

27 ± 5.3

   ≥ 30 kg/m2

103 (23.7)

49 (17.9)

Medication

  

   Verapamil

220 (50.6)

--

   Placebo

215 (49.4)

--

Event

  

   Intracoronary stent

362 (83.2)

--

   Previous CABG

17 (3.9)

--

   Previous PTCA

43 (9.9)

--

   Previous MI

156 (35.9)

--

Cardiovascular risk factor

  

   Diabetes mellitus

54 (12.4)

22 (8.0)

   Hypertension

279 (64.1)

139 (50.7)

   Hyperlipidaemia

373 (85.7)

138 (50.4)

   Current smoker

103 (23.7)

40 (14.6)

   Former smoker

163 (37.5)

47 (17.2)

Family history of CHD

166 (38.2)

n/a

Restenosis

128 (29.4)

--

  1. Data presented are number (%) of patients; plus-minus values are mean ± standard deviation. BMI body mass index, CABG coronary artery bypass grafting, PTCA percutaneous transluminal coronary angioplasty, MI myocardial infarction, CHD coronary heart disease, n/a not applicable.